Francis (Frank) J. Partel, Jr. is a retired senior executive in consumer financial services. He worked at Wriston's Citibank, American Express, Chase Manhattan Bank, Commercial Credit (with Sandy Weill), and retired from US Bancorp in Minneapolis. He holds an A.B. from Columbia College and an MBA from from Columbia Business School. He manages his own money and is a GARP/value investor. He is a former LTJG in the US Naval Reserve (1965-68) and writes modern naval fiction for sophisticated readers. A Wound in the Mind, 2007, The Chess Players, 2010.
William Block is the President and CIO of W.G. Investment Research LLC (@WG_investments). Mr. Block is a CPA with 5 years of experience in public accounting, and 2+ years of experience in the financial services industry. Mr. Block earned his Master of Accountancy degree in 2008 and his B.S. in Business Management in 2007.
Mr. Block has 10+ years of investing experience, and has been intrigued by the market from the start. Over the years, Mr. Block has learned that long-term investing is a discipline that, if followed, will help contribute to building lasting wealth. As such, most of Mr. Block's articles will be about the investments that he plans to hold for at least 3 to 5 years as long as the company's 'story' does not change. As a Seeking Alpha contributor, Mr. Block's main goal is to write about the companies that are key to his portfolio with the hope of promoting discussion (for or against the investment) from others within the SA community.
Please visit my website for more information about W.G. Investment Research LLC.
I'm retired from a near 40 year career in the publishing industry working with an international publishing company. My investing experience is over a span of 40 years. Luckily with more winners than losers! My hobbies are world travel, reading good books(non-fiction)--and researching stocks that I have an interest. In my retirement, I volunteer my time working in assisting several lawyers with their Child Protective Service cases.(Drugs are destroying our Society and family structure) I also serve as a reviewer for a national literary prize given each year.
W. (Ed) Wijaranakula has been a portfolio manager for over 15 years. He has a Ph.D. in Electronic Materials and has worked with Intel, Taiwan Semiconductor, Texas Instruments, and other tech companies in the Silicon Valley, during his professional career. He was also involved with industry research projects at MIT, NC State and the University of Washington. His investment research expertise includes biotech, commodities and currencies. He has published over 700 articles and holds 14 U.S. and international patents.
Richard J. Parsons is a former banker who writes about banking. His newest book is “Investing in Banks: Strategies and Statistics for Bankers, Directors, and Investors,” published in April by The Risk Management Association. In this book he examines long-term bank stock performance and identifies specific factors that create and destroy shareholder value.
He is also the author of Broke: America’s Banking System, published in 2013. In this book Parsons explains why the U.S. banking system has suffered nearly 3,500 bank failures over the past three decades.
Parsons is a frequent contributor to the American Banker and the Risk Management Journal. He teaches the Operational Risk Management course for the Wharton-RMA Advanced Risk Management Program as well as the Advanced Operational Risk Management course for the RMA.
The RMA Journal selected Parsons’ article -- “The Next Crisis in Banking: A Talent Crisis?” -- as the first place winner in its 2014 Journalistic Excellence Award.
Prior to writing and speaking about the banking industry, Parsons spent more than 31 years at Bank of America where he was an executive vice president and member of the Management Operating Committee. In his last role he chaired the bank’s Operational and Compliance Risk Committee and the Emerging Risk Committee.
Parsons has a BA in history from Ohio Wesleyan University and an MBA from the University of Virginia Darden School of Business.
I am a former Investment and Commercial Banker with over 30 years experience in the field. I have been advising both individuals and institutional clients on high-yield investment strategies since 1991. As author of “High Dividend Opportunities”, a premium subscription service at Seeking Alpha, my objective is to bring investors the most profitable and newest high dividend ideas, with special focus on the Energy sector. The service includes an actively managed model Portfolio targeting an overall dividend yield of 6-9% in addition to long-term capital gains. My research aims to maximize returns by identifying undervalued securities in the High Yield space.
In addition to being a Certified Public Accountant CPA from the State of Arizona, I hold a BS Degree from Indiana University, Bloomington, and a Masters degree from Thunderbird School of Global Management (Arizona). I am also a Certified Mortgage Advisor CEMAP, a UK certification. My Research and Articles have been featured on Seeking Alpha, Investing.com, ETFdailynews, and on FXEmpire.
For more information on how to subscribe to “High Dividend Opportunities” and gain exclusive access to the portfolio, live alerts and market commentaries, check the post: Introduction to “High Dividend Opportunities” on my Instablog or just email me at firstname.lastname@example.org .
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
Michael Kramer is the founder and PM of MCM.
Michael Kramer is a thematic growth investor. He likes to think about themes in society and find long term equity investments that fit those themes.
Michael is the founding member of Mott Capital Management, LLC in 2014. Prior to MCM Michael spent the previous 10 years working as a domestic and international equity trader. During this time he was responsible for handling trades in some of the most illiquid equities. Additionally, Michael has experience trading in some of the most exotic foreign markets.
Mott Capital Management is a Thematic Growth investor using themes and trends in life to find exciting growth stories. Once we find a theme we want to capitalize on we begin searching for products that interact with the end user. From there we begin the company search process. We are long-term because that is our edge. We understand and recognize when events are critical and when they are not. We also believe it is a way to neutralize market volatility.
Jesse is an experienced buy-side analyst. published author, and Chartered Financial Analyst. Previously working as an investment banking analyst with a focus on restructuring while concurrently attending the University of Connecticut (Storrs). After graduating in 2012 he wrote and published his thoughts on investments in the U.S. equities markets, which led to recruitment as a Research Analyst at Iridian Asset Management (2013 - 2016). Jesse also has professional experience analyzing legal dockets and finding special situation investment opportunities and is currently seeking new employment opportunities with Equity Investment Funds (October 2016). He is located in Stamford, CT.
Private investor who started at the age of 16 years old with a joint account with my dad. I'm now more than 50-years old. I came up through the finance ranks starting my career at Arthur Andersen & Co. I became a CFO of a private company in my early 30s and was lucky enough to be able to retire many years ago after being in the right place at the right time. I retired as the President of a $400 million partnership marketing company. My investment philosophy is to focus on companies that have the following characteristics:
- Rock solid balance sheets
- Outstanding FCFs
- Growing revenues
- Expanding margins
- Strong management team focused on driving LONG-TERM STAKEHOLDER VALUE!
I perform all my own due diligence and build all my own models. My motto is SLOW AND STEADY!!!
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.
Best tech/finance blogger on TipRanks. You can also follow Alex Cho on Twitter and WhoTrades.
Similar to how you tip your waiter/waitress for great service, you may also tip me when you find my research useful.
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) email@example.com.
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
*************Original User account: 17741882***********************
General : Aspiring Equity Analyst with 7 years of professional and personal investment experience. Primary focus is Value and Growth both domestic and abroad (Europe and Latin America)
Professional Experience: Hedge Fund Assurance and Valuation Services ( AUM 100M - 10B). Exposure to almost every investment strategy and product on the market. Strategies ranged from typical Long/Short Equity & Structured Products such as MBS and CDOs, all the way to reinsurance funds trading catastrophe linked bonds.
Licenses: CPA (NJ) Certified Public Accountant
CFA Candidate - Level 1 June 2017
Very proud Rutgers Graduate- New Brunswick Campus - GO Scarlet Knights ! -
Major: Bachelor's of Accounting
SevenSeas Investment Research was created to provide investors with honest, deeply considered, detailed, passionately conducted, straight forward, value focused, fundamental investment research on a variety of asset classes and market topics.
I use a combination of traditional value focused fundamental research and a proprietary method of stock selection that can be adjusted to meet a dynamic mixture of different risk tolerances, and various other investor criteria to construct concentrated and unique portfolios to any given individual's investment needs.
My deep knowledge of Alternative Investments and Accounting (both GAAP & IFRS), as well as my exposure to dozens of successful hedge fund portfolios and complex investment securities, provided me with a unique perspective few obtain of a side of the market unseen by the retail investor. I wish to share my passion and knowledge for the markets that has grown to an obsession over the last 7 years with the SA community, to bring value to investors ranging from beginners, all the way to seasoned professionals, and network with the thousands of talented individuals from around the world who come to the platform seeking the same objectives.
My overall mission is to provide readers with valuable research to assist them in making wise investment decisions. All articles are my own personal views, and do not constitute investment advice. **Please be sure to contact your own investment professional when considering purchasing an investment.
SevenSeas will remain dedicated to providing a complete, and consistent level of work and appreciation for the readers. The highest standards of ethics and professionalism will be displayed at all times. I welcome all feedback and can be reached via direct messaging. Best of luck to all, and I hope you enjoy the work.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
We try to provide unbiased, balanced and helpful insight into long-term prospects of the businesses we follow. We mainly base our analysis on the fundamentals and assess the long-term growth potential of the companies. In addition, we also analyze the dividend stability of different companies, and try to assess the future cash flows in order to gauge dividend growth potential.
You can also follow us on twitter here:https://twitter.com/IAEResearch
Marc Chandler has been covering the global capital markets in one fashion or another for 25 years, working at economic consulting firms and global investment banks. A prolific writer and speaker he appears regularly on CNBC and has spoken for the Foreign Policy Association. In addition to being quoted in the financial press daily, Chandler has been published in the Financial Times, Foreign Affairs, and the Washington Post. In 2009 Chandler was named a Business Visionary by Forbes.
Marc's commentary can be found at his blog (www.marctomarket.com) and twitter www.twitter.com/marcmakingsense
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the equity research company "BNL Finance". An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
I am business graduate with a professional certification in F&A. I have been associated with the academic field, teaching both short and long courses on Finance and Accounting but my passion is following and writing about good investments.
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
Analyst and Fund Manager with almost 20 years investment experience. Coverage includes a variety of industries, with a focus on technology.
Particularly focused on value stocks, poorly understood or under-followed situations, and contrarian perspectives.
Primarily invest in special situations with value that is poorly understood or not fully appreciated, or where we believe there is a highly asymetric risk/reward profile. Also look for long/short ideas in mid/larger cap names where we believe we have a variant view, and the market is dramatically mispricing value.
Follow me on Twitter @valinsights
I am a retired global analyst, currently busy in investing and writing articles about stocks at several investing publications and websites. I have also developed strategies for creating winning portfolios according to specific formulas.
In January 2015, I was ranked among the world’s top 10 financial bloggers according to TipRanks, which holds financial experts accountable for their recommendations by disclosing their stock ratings since 2009:
I write about dividend growth stocks on my website www.dividendgrowthinvestor.com.
I am mostly a buyer of high quality dividend stocks, with solid competitive advantages. My holding period is forever, as long as the dividend is at least maintained. I tend to concentrate my efforts on stocks which grow earnings and dividends, which provides outstanding total returns over time. I only focus my attention to stocks with sustainable dividend payments. I am also a firm believer in diversification accross sectors and geographic locations.
I have been focusing my attention particularly to companies that regularly increase dividends to their shareholders on my website. On my blog I share my thoughts on investing in dividend paying stocks that have consistently increased their payments over time and tips on growing my dividend income. I hope that my blog will serve as an inspiration for my readers and that it would change their financial lives for the better.
Visit my website, Dividend Growth Investor (http://www.dividendgrowthinvestor.com/)
Brad Thomas is a research analyst and he currently writes weekly for Forbes and Seeking Alpha where he maintains research on many publicly-listed REITs. In addition, Thomas is the Senior Analyst at iREIT Forbes and Editor of the Forbes Real Estate Investor, a monthly subscription-based newsletter.
Thomas has also been featured in Forbes Magazine, Kiplinger’s, US News & World Report, Money, NPR, Institutional Investor, GlobeStreet, and Fox Business. He was the #1 contributing analyst on Seeking Alpha in 2014 (as ranked by TipRanks) and he is currently writing a book on the legendary investor Donald Trump.
Thomas has co-authored a book (The Intelligent REIT Investor) that is available on Amazon.
Thomas received a Bachelor of Science degree in Business/Economics from Presbyterian College where he played basketball. He resides in South Carolina with his wife and kids.
Peter Geschek is a freelance writer, investor and the publisher of www.medfrontiers.com website. This is a site for medical innovation news and clinical trials news. Short, concise, important information about the latest is biotech and pharmaceuticals.
Theodore J. Cohen, Ph.D., a research scientist, has been an investor for more than 50 years. Since 1980, he has focused his attention on investment research and investigative analyses of companies developing therapeutic drugs in the biotech sector. Dr. Cohen is a frequent contributor of Guest Opinions (op-ed pieces) to the Bucks County (PA) Courier Times (circulation: 80,000), where, since 2007, he has addressed such varied subjects as the conflicts of interest (COIs) associated with two members of the Provenge advisory committee (AC); the U.S. Senate’s Durbin Amendment, to tighten COI reviews of FDA AC members; and naked short selling. Cohen is the author of the award-winning novels Death by Wall Street: Rampage of the Bulls (AuthorHouse, 2010) and House of Cards: Dead Men Tell No Tales (Outskirts Press, 2011), which were inspired by real events. The books are available from Amazon.com, B&N, and 26,000 online bookstores worldwide. For details, see http://www.theodore-cohen-novels.com.
Dr. Schwartz is a 30-year veteran of the Pharmaceutical Industry most recently in the role of Executive Director, Strategic Transactions for Bristol-Myers Squibb Company where he has more than a dozen completed transactions to his credit. He speaks frequently on the Biotech-Big Pharma dynamics and evolving research and treatment paradigms in oncology and is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010.
Dr. Schwartz founded RHS Advisors, LLC, a life-sciences consulting firm, in July 2010.
Ashraf Eassa is a technology specialist with The Motley Fool. He writes mostly about technology stocks, but is especially interested in anything related to chips -- the semiconductor kind, that is.
I'm A 31 Year-Old Stay-At Home Mom, Who Enjoys Writing About And Establishing Income-Driven Strategies Within Numerous Sectors. My Husband And I Are Happily Married (January 2015) And I Currently Reside In The Greater New York Area.